Rheumatological aspects of pathogenesis and treatment of COVID-19 infection

Contemporary rheumatology is a field dealing with the phenomena of autoimmune states and inflammation. Rheumatic diseases cover a wide spectrum of diseases of the musculoskeletal system, connective tissue and vessels. The occurrence of an immune, autoimmune and autoinflammatory response is often lin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Desislava Kalinova, Rasho Rashkov
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	covid-19 infection anti-rheumatic drugs rheumatic disease pneumonitis Medicine R
Acceso en línea:	https://doaj.org/article/602ef9ac23b747b4a75a2c594e26ba00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:602ef9ac23b747b4a75a2c594e26ba00
record_format	dspace
spelling	oai:doaj.org-article:602ef9ac23b747b4a75a2c594e26ba002021-12-02T19:19:24ZRheumatological aspects of pathogenesis and treatment of COVID-19 infection0034-62332084-983410.5114/reum.2020.98435https://doaj.org/article/602ef9ac23b747b4a75a2c594e26ba002020-08-01T00:00:00Zhttps://www.termedia.pl/Rheumatological-aspects-of-pathogenesis-and-treatment-of-COVID-19-infection,18,41653,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834Contemporary rheumatology is a field dealing with the phenomena of autoimmune states and inflammation. Rheumatic diseases cover a wide spectrum of diseases of the musculoskeletal system, connective tissue and vessels. The occurrence of an immune, autoimmune and autoinflammatory response is often linked to different kinds of infections. Which aspects of the coronavirus infection relate to rheumatological therapy and practice? In order to answer this question one needs to look at the pathogenesis of the SARS-CoV-2 infection. Antimalarial drugs may block antigen presentation of the viral peptides from antigen presenting cells, as they may alter the lysosomal proteases that mediate the viral entry in the cells and have demonstrated efficacy in improving the infection. Anti-IL-6 may interfere with cytokine storm in severe cases and use of tocilizumab has had good results in a small cohort. Baricitinib not only plays a role in inhibiting the synthesis of cytokines but it also has a function in suppressing receptor-mediated endocytosis. The constantly new and tested concepts in the treatment of COVID testify to the growing knowledge about the virus, but also to the need for more targeted therapy. Treatment regimens have been developed for both patients with COVID-19 and those with symptomatic SARS-CoV infection and rheumatic disease. This article is an attempt to discuss the management of COVID-19 and coexisting rheumatic disease.Desislava KalinovaRasho RashkovTermedia Publishing Housearticlecovid-19 infection anti-rheumatic drugs rheumatic disease pneumonitisMedicineRENRheumatology, Vol 58, Iss 4, Pp 231-235 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 infection anti-rheumatic drugs rheumatic disease pneumonitis Medicine R
spellingShingle	covid-19 infection anti-rheumatic drugs rheumatic disease pneumonitis Medicine R Desislava Kalinova Rasho Rashkov Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
description	Contemporary rheumatology is a field dealing with the phenomena of autoimmune states and inflammation. Rheumatic diseases cover a wide spectrum of diseases of the musculoskeletal system, connective tissue and vessels. The occurrence of an immune, autoimmune and autoinflammatory response is often linked to different kinds of infections. Which aspects of the coronavirus infection relate to rheumatological therapy and practice? In order to answer this question one needs to look at the pathogenesis of the SARS-CoV-2 infection. Antimalarial drugs may block antigen presentation of the viral peptides from antigen presenting cells, as they may alter the lysosomal proteases that mediate the viral entry in the cells and have demonstrated efficacy in improving the infection. Anti-IL-6 may interfere with cytokine storm in severe cases and use of tocilizumab has had good results in a small cohort. Baricitinib not only plays a role in inhibiting the synthesis of cytokines but it also has a function in suppressing receptor-mediated endocytosis. The constantly new and tested concepts in the treatment of COVID testify to the growing knowledge about the virus, but also to the need for more targeted therapy. Treatment regimens have been developed for both patients with COVID-19 and those with symptomatic SARS-CoV infection and rheumatic disease. This article is an attempt to discuss the management of COVID-19 and coexisting rheumatic disease.
format	article
author	Desislava Kalinova Rasho Rashkov
author_facet	Desislava Kalinova Rasho Rashkov
author_sort	Desislava Kalinova
title	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
title_short	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
title_full	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
title_fullStr	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
title_full_unstemmed	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
title_sort	rheumatological aspects of pathogenesis and treatment of covid-19 infection
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/602ef9ac23b747b4a75a2c594e26ba00
work_keys_str_mv	AT desislavakalinova rheumatologicalaspectsofpathogenesisandtreatmentofcovid19infection AT rashorashkov rheumatologicalaspectsofpathogenesisandtreatmentofcovid19infection
_version_	1718376854940811264

Rheumatological aspects of pathogenesis and treatment of COVID-19 infection

Ejemplares similares